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ABSTRACT
Objective: The use of transcatheter aortic valve
implantation (TAVI) is growing rapidly in countries with
a predominantly elderly population, posing a huge
challenge to healthcare systems worldwide. The
increment of human and economic resource
consumption imposes a careful monitoring of clinical
outcomes and cost-benefit balance, and this article is
aimed at analysing clinical outcomes related to the
TAVI learning curve.
Methods: Outcomes of 177 consecutive transfemoral
TAVI procedures performed in 5 years by a single team
were analysed by the Cumulative Sum of failures
method (CUSUM) according to the clinical events
comprised in the Valve Academic Research Consortium
(VARC-2) safety end point and the VARC-2 definition of
device success. Margins for events acceptance were
extrapolated from landmark trials that tested both
balloon or self-expandable percutaneous valves.
Results: 30-day and 1-year survival rates were 97.2%
and 89.9%, respectively. Achievement of the primary
end point (number of cases needed to provide the
acceptable margin of the composite end point of any
death, stroke, myocardial infarction, life-threatening
bleeding, major vascular complications, stage 2–3
acute kidney injury and valve-related dysfunction
requiring a repeat procedure) required the performance
of 54 cases, while the learning curve to achieve ‘device
success’ identified 32 cases to reach the expected
proficiency. In this experience, the baseline clinical risk
as assessed by the Society of Thoracic Surgeons (STS)
score determined the long-term survival rather than the
adverse events related to the learning curve.
Conclusions: A relatively large number of cases are
required to achieve clinical outcomes comparable to
those reported in high-volume centres and controlled
trials. According to our national workload standards,
this represents more than 2 years of continuous
activity.
INTRODUCTION
Transcatheter aortic valve implantation
(TAVI) is a safe therapeutic alternative to sur-
gical aortic valve replacement (SAVR) in
inoperable and high-risk patients.1–3
The superiority of TAVI over medical therapy
has been shown in inoperable patients.1 It is
also non-inferior compared with SAVR in
high-risk patients2 and self-expandable valves
are even better than SAVR.3
Transcatheter interventional options for
high-risk patients with aortic valve stenosis
(AVS) have dramatically changed the thera-
peutic perspectives in a very short lapse of
time, posing a huge therapeutic challenge to
healthcare systems worldwide. Given the
KEY QUESTIONS
What is already known about this subject?
▸ Very little is known as to the number of cases
required to overcome complications and failures
of transcatheter aortic valve implantation (TAVI)
at centres that start their activity in high-risk
aortic patients. Some authors have shown an
improvement in ancillary indicators of outcome
with growing experience such as procedural
time, dose of contrast media and radiation
exposure, but differences in clinical terms have
not been reported.
What does this study add?
▸ This study identifies a precise number of trans-
femoral TAVI cases needed to overcome the
learning curve, using a dedicated statistical
method that is regularly applied to monitor the
operator’s performances in cardiac surgery over
time.
How might this impact on clinical practice?
▸ Our results indicate that a relatively long period
of activity (about 2 years) is needed to warrant
acceptable clinical outcomes during the start-up
phase. Therefore, TAVI procedures should be
concentrated in high-volume centres, and a
proctoring on-site should be maintained over
the first 50 cases rather than the few 8 or 10
currently advised by the valve manufacturers.
This would optimise clinical outcomes from the
beginning of a TAVI experience with a beneficial
impact on clinical and economic results.
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exponential growth of the workload represented by the
elderly population with AVS, more centres are rapidly
getting involved in this new treatment modality, and the
consequent increment of human and economic
resource consumption imposes a careful monitoring of
clinical outcomes and cost-beneﬁt balance.4
The present article reports on the TAVI experience of
an Italian centre performing the ﬁrst case in March
2010 and describes the evolution and results of the tech-
nique over 5 years of continuous activity.
The aim of this report is to analyse the immediate and
follow-up clinical outcomes of a TAVI programme since
its implementation in relation to the learning curve, as
an opportunity for evaluating results and determining
options for further improvement.
METHODS
Study design, aims and patient population
Prospective single-centre study aimed at analysing retro-
spectively the safety and efﬁcacy of TAVI performed in
patients with symptomatic AVS categorised as high risk,
performed between March 2010 and March 2015 at the
University Hospital of Verona, Italy.
Inclusion criteria were presence of severe symptomatic
AVS; high surgical risk predicted by a logistic European
System for Cardiac Operative Risk Evaluation
(EuroSCORE)5 ≥20% or Society of Thoracic Surgeons
(STS)6 score ≥10%. Patients at lower surgical risk
(EuroSCORE<20%) were included when presenting
comorbidities not well captured by current risk scores,
such as porcelain aorta, previous chest radiotherapy,
severe obstructive pulmonary disease, previous organ
transplantation or any previous cardiac surgery.
Exclusion criteria were mechanical aortic prosthesis,
obstructive hypertrophic cardiomyopathy, intraventricu-
lar masses, sepsis or active endocarditis, and diseases
with a <2-year life expectancy. All patients included in
this analysis provided written informed consent as
required by the Health Technology Assessment Agency
of the Regione Veneto.
Clinical follow-up was planned at 1, 6 and 12 months
and then yearly to assess: vascular complications; need
for permanent pacemaker (PPM) implantation and
renal function; functional status (New York Heart
Association (NYHA) classiﬁcation) and clinical events:
death, myocardial infarction (MI), stroke and heart
failure needing rehospitalisation. The survival status was
determined by direct clinical contact of all living
patients, or by veriﬁcation of death certiﬁcates in all
fatal cases.
The primary end point was: the learning curve analysis
for TAVI procedures performed by a single interven-
tional team, aimed at detecting a correlation between
experience and the 30-day safety composite end point
included in the Valve Academic Research Consortium
(VARC-2), that is, any death, stroke, periprocedural MI,
life-threatening bleeding, major vascular complications,
stage 2–3 acute kidney injury (AKI) and valve-related
dysfunction requiring a repeat procedure.7 The
Cumulative Sum of failures Analysis (CUSUM) was used
to assess the team performances over time.8
Secondary end points: learning curve analysis for VARC-2
device success;7 the global survival rate at 30 days and
1 year; the survival-free from the composite of death
from any cause, stroke, MI and rehospitalisation for
heart failure, at 30 days, and 1 year.
Clinical events were adjudicated by an internal com-
mittee that followed each patient during the ﬁrst year
follow-up. The same three TAVI operators performed all
the procedures during the study period.
Devices and procedure
Both Edwards SAPIEN (Edwards Lifesciences, Irvine,
California, USA) and Medtronic CoreValve (Medtronic,
Minneapolis, Minnesota, USA) were implanted. The ﬁrst
17 cases were performed with the SAPIEN Novaﬂex 23F
system, the ﬁrst 8 of which were proctored by an exter-
nal expert. From case number 18, the SAPIEN XT valve
replaced the Novaﬂex. From July 2012, the Medtronic
CoreValve prosthesis was also implemented in the
routine practice, the ﬁrst 6 cases also being proctored by
an external expert.
Indications to TAVI and the access site for valve
implantation were discussed and decided by the
Institutional Heart Team. This analysis of the learning
curve refers to the transfemoral experience only.
Indeed, transapical TAVI was performed in 25 cases
during the same study period but was not included in
this study.
All patients received dual antiplatelet therapy with
standard loading doses of aspirin and clopidogrel before
the procedure. At follow-up, only one antiplatelet agent
was continued (usually aspirin), or oral anticoagulation
when clinically indicated. Patients treated with coronary
angioplasty received either bare metal, or second-
generation drug-eluting stents, and dual antiplatelet
therapy or a triple association (when required) were was
maintained from 1 or 3 months respectively. All patients
stayed in the intensive care unit during the ﬁrst 24 hours
after the procedure and then were transferred to the
cardiology ward if no complications ensued.
Definitions
Cardiovascular mortality, MI, stroke, AKI, bleeding, vas-
cular complications, device success and residual aortic
regurgitation (AR) were deﬁned according to the
VARC-2 recommendations.7 Clinical risk was ranked
according to the logistic EuroSCORE5 the new
EuroSCORE-II9 and the STS score.6
Statistical analysis
Categorical data are expressed as numbers and percen-
tages, and compared by χ2 test, as appropriate.
Continuous variables are reported as mean±SD for
normal distributions are otherwise reported as median
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±IQR. Differences between means were tested by the
t-test or Mann-Whitney U test, where appropriate.
Univariate and multivariate stepwise Cox regression ana-
lyses were performed to identify independent predictors
of events. ORs and their corresponding 95% CIs are pro-
vided. Cumulative survival curves were drawn using the
Kaplan-Meier method, and the log-rank test was used to
compare differences between groups. The learning
curve of the TAVI procedure was evaluated using an
unadjusted CUSUM.8 This method, initially created for
industrial analyses, can generate quality control charts
for monitoring the operator’s performances over time.
On the vertical axis is reported the cumulative number
of failures, whereas the horizontal axis reports the oper-
ation number in a consecutive fashion (I). The end
point (failure) deﬁnition is reported for each chart.
Type I(α) and type II(β) errors were both set at 0.05. To
identify acceptable (lower p0) and unacceptable (higher
p1) failure limits, end points incidence reported in
seminal high-risk TAVI trials was analysed (Partner ‘B’,1
US Pivotal Trial,3 CHOICE Trial)10 and used to calculate
the boundaries for the control charts. Rates of 30 days
VARC-2 safety end point in such trials indicated a 20%
threshold as ‘acceptable’, while a 30% rate was consid-
ered unacceptable. Following the same method, the pro-
cedural non-success acceptable limit was set at 10%,
while a 20% rate denoted an out of control procedure.
Since major bleeding alone occurred in 17–25% of
cases, the limits for the CUSUM regarding this event
plus the primary end point were set, respectively, at 30%
and 40%. The lower boundary was constructed using the
formula L0=I{ln[(1−p0/1−p1)]/ln(OR)}−{ln[(1−α)/
β]/[ln(OR)]}, and the higher boundary using the
formula L1=I{ln[(1−p0/1−p1)]/ln(OR)}+{ln[(1−β)/α]/
[ln(OR)]}, where I is the operation number and OR is
deﬁned as [p1(1−p0)]/[p0(1−p1)]. When the cumula-
tive failure line intersects the lower boundary, the team’s
performance is considered proﬁcient. A p value <0.05
for two-sided tests was considered statistically signiﬁcant.
Statistical analysis was carried out using the statistical
software SPSS V.20.0 (SPSS, Chicago, Illinois, USA).
RESULTS
Baseline characteristics and procedure details
A total of 177 patients were analysed. Baseline character-
istics are shown in table 1. The logistic EuroSCORE was
≥20% in 100 patients (56.5%), and 10–20% in 77
(43.5%).
Procedural details are listed in table 2.
As for the initial manufacturer’s indications, vascular
access was obtained with surgical approach in the ﬁrst
20 patients (11.2%), and then percutaneous access was
performed in all cases. The same percutaneous closure
device (Prostar, Abbott, Abbott Park, Illinois, USA) was
used in all cases. No patient died or needed surgery
during the TAVI procedure. Valve-related dysfunction
occurred in four cases (2.3%): one case of embolisation
of an Edwards valve during the delivery phase, and in
the other three cases because of a severe AR after a ﬁrst
CoreValve (two cases) or a ﬁrst Edwards valve (one
case). In all cases, the implantation of a second valve
was successful.
Clinical outcomes
The global survival rate at 30 days and 1 year was 97.2%
and 89.9%, respectively. The survival-free from the com-
posite of death from any cause, stroke, MI and rehospita-
lisation for heart failure, at 30 days and 1 year was 95.5%
and 76%, respectively.
Nine patients (5.1%) suffered AKI with increment of
creatinine levels >26.4 μmol/L compared with baseline
(7). In seven cases, AKI was stage 1, and in two patients
transient kidney replacement therapy was required
(stage 3 AKI), but in all cases creatinine levels returned
to baseline; and no patient needed permanent dialysis.
Implantation of a PPM was necessary in 14 cases (7.9%),
Table 1 Baseline characteristics
Variables Total population (177)
Age, years 80.8±7.7
Logistic EuroSCORE (%) 28.6±20.1
Male, n (%) 79 (44.6%)
BMI, kg/m2 24.7±6.2
GFR<30 mL/min, n (%) 41 (23.2%)
Anaemia,* n (%) 91 (51.4%)
Dyslipidaemia, n (%) 127 (71.8%)
COPD, n (%) 47 (26.6%)
Diabetes, n (%) 59 (33.3%)
Hypertension, n (%) 150 (84.7%)
Previous AMI, n (%) 40 (22.6%)
Atrial fibrillation, n (%) 66 (37.3%)
Previous stroke, n (%) 15 (8.5%)
PVD, n (%) 79 (44.6%)
CAD, n (%) 105 (59.3%)
Previous CABG, n (%) 35 (19.8%)
Previous AVR, n (%) 10 (5.6%)
Previous MVR, n (%) 3 (1.7%)
PM, n (%) 19 (10.7%)
Syncope, n (%) 52 (29.4%)
Stable angina, n (%) 66 (37.3%)
Unstable angina, n (%) 12 (6.8%)
Cardiogenic shock, n (%) 59 (33.3%)
NYHA class I or II, n (%) 30 (17%)
NYHA class III or IV, n (%) 147 (83%)
Recent PCI, n (%) 24 (13.6%)
Continuous variables are expressed as average±SD.
*Anaemia: cut-off Hb≤13 g/dL for male, Hb≤12 g/dL for female.
AMI, acute myocardial infarction; AVR, aortic valve replacement;
BMI, body mass index; CABG, coronary artery bypass graft; CAD,
coronary artery disease; COPD, chronic obstructive pulmonary
disease; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; GFR, glomerular filtration rate (based on
Cockroft-Gault); MVR, mitral valve replacement; NYHA, New York
Heart Association; PM, pacemaker; PVD, peripheral vascular
disease; recent PCI, percutaneous coronary intervention
<3 months before TAVI; TAVI, transcatheter aortic valve
implantation.
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of which 9 were after Medtronic CoreValve (17.6%), and
5 after Edwards SAPIEN (4%).
Primary end point: Figure 1A shows the relation
between the learning curve and the 30-day VARC-2
safety end point included in the model. The perform-
ance of 54 cases was found to determine a level of
‘acceptable performance’ according to the prespeciﬁed
parameters. Figure 1B indicates the primary end point
for either the balloon of the self-expandable valve types.
Occurrence of singular clinical events is shown in
table 3.
Secondary end points: Figure 1C shows the relation
between the number of cases performed and device
success.
When the clinical outcomes were correlated to the
learning curve adjusting for the baseline clinical risk,
the results were identical since the risk proﬁle of the
patients’ population was the same during the whole dur-
ation of the study (mean logistic EuroSCORE,
EuroSCORE-II and STS in the ﬁrst 53 patients vs subse-
quent cases: 27.7% vs 29.4% (p=0.63), 11.7% vs 11.7%
(p=0.99) and 8.9% vs 9.2% (p=0.83), respectively).
Therefore, our results related to the learning curve
apply to very high-risk patients, and may differ in lower
risk populations.
The contrast media used during the procedure
amounted to 156.8±10 mL (161.5 for the ﬁrst 53 cases vs
153.9 from case 54, p=0.59). Also, the procedural and
ﬂuoroscopy times show a downward trend between the
two groups of patients: from 114.5 to 102.4 (p=0.15)
and from 22.2 to 18.7 (p=0.7) minutes, respectively.
Median hospital stay was 10 days (IQR=5–14 days), of
which 2 were in the intensive care unit. There was a
signiﬁcant reduction of the hospital stay from case 54
(12 days, IQR=5–18 days vs 9 days, IQR=5–12 days;
p=0.005), with a reduction also of the intensive care
from 2 (IQR=1–3 days) days to 1 (IQR=0.5–2 days) day
(p=0.02).
At univariate analysis, predictors of the primary end
point were previous stroke (OR=4.9; 95% CI 2.1 to 9.17;
p=0.001) and coronary artery disease (OR=2.67; 95% CI
1 to 7.1; p=0.05). Of these, only previous stroke
(OR=4.51; 95% CI 1.8 to 10.2; p<0.001) was an inde-
pendent predictor of the primary end point at a multi-
variate analysis.
Long-term outcome: Survival-free of major events was
analysed in all patients who reached 1 year after the pro-
cedure (129). The global survival rate was 89.9%.
Patients with a EuroSCORE≥20% had a trend to higher
mortality from any cause than patients with a
EuroSCORE<20% (13.3% vs 5.6%, p=0.24). According
to EuroSCORE-II, mortality was 15% in the group ≥10%
and 9.2% in the group <10% (p=0.42), and according
to the STS score it was 19% in those with STS≥10% and
5.7% in STS score <10 (p=0.028). Cardiovascular events
accounted for one-third of the total causes of death
during the follow-up period. It is worth mentioning that
survival at 1 year was signiﬁcantly different according to
the degree of residual AR after TAVI (regardless of the
type of valve; ﬁgure 2). At 1 year, stroke occurred in
5.4% of cases, MI in 2.3% of patients, heart failure in
10.9% and the composite event rate of death, stroke, MI
and heart failure needing hospitalisation occurred in
24% of patients. No statistically signiﬁcant difference in
mortality (11.3% vs 9.2%, p=0.77) or in the composite
event rate (30.2% vs 19.7%, p=0.21) was observed at
Table 2 Procedural details according to device
Variables Total population (177)
Edwards
SAPIEN
(126) Medtronic CoreValve (51) p Value
Preventive PCI pre-TAVI, n (%) 24 (13.6%) 17 (13.5%) 7 (13.7%) 0.99
Iliac PTA before TAVI, n (%) 15 (8.5%) 8 (6.3%) 7 (13.7%) 0.14
PCI during TAVI, n (%) 6 (3.4%) 3 (2.4%) 3 (5.9%) 0.54
Valvular pathology, n (%)
AS 142 (80%) 115 (91.3%) 27 (52.9%)
AS+AR 25 (14.1%) 8 (6.3%) 17 (33.3%)
Degenerated aortic prosthesis (VIV) 10 (5.6%) 3 (2.4%) 7 (13.7%)
Prosthesis size, n (%)
20 mm 1 (0.6%) 1 (0.8%) 0
23 mm 56 (31.6%) 51 (40.5%) 5 (9.8%)
26 mm 74 (41.8%) 61 (48.4%) 13 (25.5%)
29 mm 38 (21.5%) 13 (10.3%) 25 (49%)
31 mm 8 (4.5%) 0 8 (15.7%)
Balloon post dilation, n (%) 13 (7.3%) 4 (3.2%) 9 (17.6%) 0.002
Conversion to heart surgery, n (%) 0 0 0
Death during procedure, n (%) 0 0 0
VARC-2 device non-success, n (%) 6 (3.4%) 4 (3.2%) 2 (3.9%) 0.99
AR, aortic regurgitation; AS, aortic stenosis; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty; VARC-2,
Valve Academic Research Consortium; VIV, valve in valve.
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Figure 1 (A) CUSUM analysis for the primary end point (VARC-2 safety end point at 30 days composite of: death, stroke,
life-threatening bleeding, major vascular complications, AKI stage 2–3 and valve-related dysfunction requiring a repeat
procedure), showing in-control procedure. Formal proficiency was obtained at operation n.54 when the cumulative failure curve
crossed the predicted lower reference (estimated 20%). (B) CUSUM analysis for the primary end point for Edwards
balloon-expandable valves (n=126) and CoreValve self-expandable valves (n=51). Formal proficiency was obtained at operation
n.50 for Edwards (yellow line) and operation n. 36 for CoreValve (red line) prostheses. Of note, our centre began the TAVI
programme with Edwards devices; therefore, early CoreValve implants may have benefited from the acquired experience. (C)
CUSUM analysis for secondary end point (VARC-2 device non-success). Acceptable event rate was set to 10% and the total
number of failures were six. Proficiency level for this end point was formally reached after 32 cases. AKI, acute kidney injury;
CUSUM, Cumulative Sum of failures Analysis; TAVI, transcatheter aortic valve implantation; VARC-2, Valve Academic Research
Consortium.
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1 year between the ﬁrst 53 cases and the rest. Patients in
NYHA class I or II were 17% before TAVI and 70% after
1 year. Renal function improved signiﬁcantly, in particu-
lar among those with the worst estimated glomerular ﬁl-
tration rate before TAVI: serum creatinine changed from
163.7±114.4 μmol/L at baseline to 127.6±52.8 μmol/L at
1 year, p=0.015.
DISCUSSION
Our study reports the immediate and 1-year clinical out-
comes of a consecutive series of high-risk patients with
symptomatic AVS treated with transfemoral TAVI mostly
performed with ﬁrst-generation transcatheter valve
systems in a single Italian institution from its learning
period. The study population is comparable to that
enrolled in the Partner Trial cohort B that had a mean
logistic EuroSCORE of 26.4%.11 Recent studies have
enrolled lower risk patients: the CoreValve US Pivotal
High-Risk Study had a mean logistic EuroSCORE of
17.6%,3 similar to other European series (EuroSCORE:
21.9%, 18.5% and 14.7%, respectively).12–14
The degree of expertise developed during a 5-year
period of activity before the advent of the most recent
devices suggests the following results:
More than 50 cases are required to control the most
relevant complications, and 32 to avoid device non-
success. These numbers take into account the use of
balloon-expandable and self-expandable aortic bio-
prosthesis, the latter requiring smaller numbers most
likely because of the experience previously acquired
with the former, a result that conﬁrms the validity of the
CUSUM model. The use of the two valve types reﬂects
the needs of a referral centre that receives a high risk
and complex population.
Our experience suggests that the good performance
of the transcatheter valves since the ﬁrst models, the
accurate diagnostic workout and a ﬁrst learning process
assisted by an on-site proctor enable a reliable start-up
Table 3 Events at 30 days
Variables
30 days
(177
patients)
30 days
(first 53
cases)
30 days
(last 124
cases)
Death, n (%) 5 (2.8%) 2 (3.8%) 3 (2.4%)
Cardiovascular 2 (1.1%) 1 (1.9%) 1 (0.8%)
Non-cardiovascular 3 (1.7%) 1 (1.9%) 2 (1.6%)
Stroke, n (%) 4 (2.3%) 2 (3.8%) 2 (1.6%)
AMI, n (%) 0 0 0
Major vascular
complications, n (%)
18 (10.2%) 6 (11.3%) 12 (9.7%)
Life-threatening
bleeding, n (%)
6 (3.4%) 2 (3.8%) 4 (3.2%)
AKI, n (%) 9 (5.1%) 3 (5.7%) 6 (4.8%)
Stage 1 7 (4%) 3 (6.1%) 4 (3.2%)
Stage 2 or 3 2 (1.1%) 0 2 (1.6%)
PPM post-TAVI, n (%) 14 (7.9%) 2 (3.8%) 12 (9.7%)
30-day safety end
point, n (%)
24 (13.6%) 8 (15.1%) 16 (12.9%)
AKI, acute kidney insufficiency; AMI, acute myocardial infarction;
PPM, permanent pacemaker; RBC, red blood cell units; TAVI,
transcatheter aortic valve implantation.
Figure 2 Survival curve at 1 year follow-up (129 patients) according to the entity of residual AR: the figure shows a significant
survival reduction when residual AR was moderate (independently of the type of valve). Event rates were calculated by the
Kaplan-Meier method and compared with the use of the log-rank test. AR, aortic regurgitation.
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period with good long-term results despite relatively fre-
quent complications, mainly related to the vascular
access site. However, it is worth mentioning that
although a trend towards better clinical outcomes was
apparent with more experience, the long-term survival
was not strongly affected by the learning curve-related
events, but rather by the baseline risk as identiﬁed by
the STS score.
Our results related to the learning curve do not ﬁnd a
comparison in available publications. A ﬁrst assessment
of the TAVI learning curve was performed by Webb and
colleagues.15 In a rough analysis comparing the clinical
outcomes obtained in the ﬁrst half of their 270 patients
caseload versus the second half, a trend towards better
clinical outcomes was observed in the second half, but
these later patients had a signiﬁcantly lower STS risk
score (8.5%) compared with the former (10.5%), p=0.01.
Subsequently, Alli et al16 monitored the duration of the
intervention, the contrast media amount and the ﬂuoros-
copy time, and compared the ﬁndings observed in tertiles
based on sequence. Despite the small sample size of this
analysis (44 cases), the authors claimed that 30 cases
were needed to improve some procedural results with the
Edwards Sapien valve, but the clinical outcomes were not
analysed. Following these ﬁndings, Cerillo et al17 argued
that the CUSUM analysis would be more a sensible mean
to detect deviations from the expected clinical outcomes
and suggested that this method should be used to
monitor clinical expertise rather than procedural surro-
gates. Accordingly, our study has detected a precise
number of cases needed to deﬁne the learning curve
process using the proposed CUSUM analysis as ﬁrst
described by Rogers et al.8 This ﬁnding supports the
goodness of the CUSUM applied in interventional cardi-
ology as initially estimated by Cerillo et al.17
Other observations derived from our experience are
aligned with previous data.
Overall mortality at 30 days (2.8%) is low comparable
to that observed in monitored high-volume centres18
and much lower than that predicted by the logistic
EuroSCORE (28.6%). Other risk scores are needed to
better assess periprocedural risks in complex TAVI candi-
dates. Despite the complexity of the procedure and the
administration of contrast media, AKI occurs in very few
cases (5.1%) and no patient needed permanent dialysis
after the procedure. This ﬁnding suggests that the
improvement of renal perfusion after a percutaneous
replacement of the stenotic aortic valve largely super-
sedes the possible risks of renal damage related to the
procedure. PPM implantation was needed in <8% of
cases within 30 days with a signiﬁcantly higher rate with
the implantation of the ﬁrst-generation CoreValve.
Other series reported a PPM implantation of around
15%.12–14 Lower rates of PPM implantation are expected
with the availability of new valve types.
Major stroke occurred in 2.3% of cases at 30 days and
5.4% within 1 year; most cases reported in the long term
occurred in patients with atrial ﬁbrillation.
The rate of rehospitalisation for heart failure at
30 days was low, but it increased to 9% at 6 months, and
10.9% at 1 year. This complication is most likely related
to the multiple comorbidities of the elderly rather than
to the procedure itself, and was always managed by
medical therapy adjustment.
CONCLUSION
The clinical results of this initial experience replicate those
obtained in randomised studies and in large series per-
formed in centres of excellence. This is coherent with our
observation of a similar clinical outcome at 1 year regardless
of the learning curve. Patient selection granted by a Heart
Team discussion, a meticulous diagnostic workout and a
learning period assisted by an expert proctor on-site allow
to obtain good clinical results since the beginning of a TAVI
programme. This concept, however, applies to a large
volume interventional centre with all necessary facilities,
and a previous consolidated experience in coronary, struc-
tural and peripheral endovascular therapeutics performed
by the same operators. Nevertheless, a relatively large
number of cases were needed to reduce the most common
periprocedural complications that negatively impact the
length of hospital stay and resource consumption.
A careful monitoring of the learning curve may there-
fore have important clinical and economic implications
in the perspective of a more widespread availability of
TAVI procedures. Indeed, in-hospital complications are
common at the beginning, and a relatively large number
of cases are needed to obtain proﬁciency, a work volume
that in most European countries would require about
2 years of activity according to some national statistics.19
On-site proctoring and monitoring during this period
may prove cost-effective. However, with the advent of
smaller, simpler and more effective transcatheter valve
systems, the learning curve will most likely be shorter in
the near future. Similarly, the entity of the residual AR
will most likely decline with new valves, and this may
have an important impact on the long-term survival of
patients with TAVI. All these are important considera-
tions given the high cost of the procedure, the continu-
ous growth of the elderly population with AVS and the
parallel exponential increment of the need for TAVI.
Study limitations
This is a single-centre experience that started in 2010.
As such, the use of the very ﬁrst valve designs is limited
to few cases, therefore reducing the chance of complica-
tions that were common in the ﬁrst TAVI era. On the
other hand, the most recent valve models that signiﬁ-
cantly reduce complications (mainly vascular and
residual AR) are not included in this analysis. The stan-
dardised screening and procedures, and the complete-
ness of follow-up may provide however, results that are
indicative of a developing experience from learning to
proﬁciency also elsewhere.
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